Haemonetics Future Growth
Future criteria checks 4/6
Haemonetics is forecast to grow earnings and revenue by 21.1% and 6.8% per annum respectively. EPS is expected to grow by 19.8% per annum. Return on equity is forecast to be 19.1% in 3 years.
Key information
21.1%
Earnings growth rate
19.8%
EPS growth rate
Medical Equipment earnings growth | 18.2% |
Revenue growth rate | 6.8% |
Future return on equity | 19.1% |
Analyst coverage | Good |
Last updated | 24 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 1,594 | 252 | 232 | 344 | 3 |
3/31/2026 | 1,451 | 196 | 207 | 281 | 7 |
3/31/2025 | 1,374 | 158 | 129 | 201 | 8 |
3/31/2024 | 1,295 | 126 | 139 | 218 | 8 |
12/30/2023 | 1,270 | 127 | 129 | 197 | N/A |
9/30/2023 | 1,239 | 128 | 199 | 262 | N/A |
7/1/2023 | 1,219 | 137 | 176 | 250 | N/A |
4/1/2023 | 1,169 | 115 | 163 | 273 | N/A |
12/31/2022 | 1,129 | 96 | 128 | 261 | N/A |
10/1/2022 | 1,084 | 86 | 116 | 260 | N/A |
7/2/2022 | 1,026 | 68 | 88 | 216 | N/A |
4/2/2022 | 993 | 43 | 76 | 172 | N/A |
1/1/2022 | 953 | 23 | 33 | 106 | N/A |
10/2/2021 | 934 | 31 | 54 | 110 | N/A |
7/3/2021 | 903 | 64 | 52 | 95 | N/A |
4/3/2021 | 870 | 79 | 72 | 109 | N/A |
12/26/2020 | 884 | 108 | 118 | 154 | N/A |
9/26/2020 | 903 | 106 | 120 | 167 | N/A |
6/27/2020 | 946 | 96 | 119 | 167 | N/A |
3/28/2020 | 988 | 77 | 109 | 158 | N/A |
12/28/2019 | 999 | 80 | 81 | 132 | N/A |
9/28/2019 | 988 | 68 | 51 | 111 | N/A |
6/29/2019 | 977 | 49 | 39 | 139 | N/A |
3/30/2019 | 968 | 55 | 40 | 159 | N/A |
12/29/2018 | 952 | 46 | 72 | 196 | N/A |
9/29/2018 | 939 | 21 | 82 | 204 | N/A |
6/30/2018 | 922 | 23 | 116 | 205 | N/A |
3/31/2018 | 904 | 46 | 146 | 220 | N/A |
12/30/2017 | 898 | -17 | 126 | 197 | N/A |
9/30/2017 | 892 | 4 | N/A | 187 | N/A |
7/1/2017 | 887 | 4 | N/A | 167 | N/A |
4/1/2017 | 886 | -26 | N/A | 160 | N/A |
12/31/2016 | 900 | 16 | N/A | 178 | N/A |
10/1/2016 | 906 | -59 | N/A | 155 | N/A |
7/2/2016 | 905 | -66 | N/A | 143 | N/A |
4/2/2016 | 909 | -56 | N/A | 122 | N/A |
12/26/2015 | 893 | -50 | N/A | 124 | N/A |
9/26/2015 | 891 | 26 | N/A | 119 | N/A |
6/27/2015 | 899 | 20 | N/A | 123 | N/A |
3/28/2015 | 910 | 17 | N/A | 127 | N/A |
12/27/2014 | 925 | 30 | N/A | 123 | N/A |
9/27/2014 | 935 | 30 | N/A | 142 | N/A |
6/28/2014 | 943 | 39 | N/A | 140 | N/A |
3/29/2014 | 939 | 35 | N/A | 140 | N/A |
12/28/2013 | 947 | 38 | N/A | 116 | N/A |
9/28/2013 | 953 | 31 | N/A | 94 | N/A |
6/29/2013 | 935 | 21 | N/A | 98 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HAZ's forecast earnings growth (21.1% per year) is above the savings rate (0.6%).
Earnings vs Market: HAZ's earnings (21.1% per year) are forecast to grow faster than the German market (14.8% per year).
High Growth Earnings: HAZ's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: HAZ's revenue (6.8% per year) is forecast to grow faster than the German market (5.4% per year).
High Growth Revenue: HAZ's revenue (6.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HAZ's Return on Equity is forecast to be low in 3 years time (19.1%).